Jump Financial’s Galectin Therapeutics GALT Stock Holding History

Jump Financial’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,200	Closed	-$48K	–	1668
2021 Q4	$48K	Buy	+23,200	New	+$66.2K	﹤0.01%	1311

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Jump Financial's GALT Position: Q1 2022 in Review

Jump Financial sold out of Galectin Therapeutics (GALT) in Q1 2022, closing a stake of 23,200 shares — an estimated $48K sold.

Jump Financial first reported a position in GALT in Q4 2021 and held it in 1 quarter. The position peaked at $48K in Q4 2021. 60 funds tracked by Wall St. Rank hold GALT as of Q1 2022.

Jump Financial reported no remaining Galectin Therapeutics position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 23,200 Galectin Therapeutics shares in Q1 2022, an estimated $48K.
Jump Financial first reported a position in Galectin Therapeutics in Q4 2021 and held it in 1 quarter.
Jump Financial's Galectin Therapeutics position peaked at $48K in Q4 2021.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.